Gentian Diagnostics: First quarter 2026 report
Moss, 6 May 2026
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests, today announced its results for the first quarter of 2026.
Highlights include: • Q1 2026 sales amounted to NOK 43.9 million versus NOK 44.5 million in Q1 2025 (-1%), reflecting timing of shipments rather than underlying demand. The organic growth was 4% in Q1’26 vs Q1’25. • EBITDA of NOK 5.0 million in Q1 2026 vs NOK 14.0 million in Q1 2025. Profit before tax of -27.6 million, of which 30.2 million is related to an impairment of the NT-proBNP development project.
• Gross margin of 53% (64% in Q1’25) influenced by adverse currency developments and higher raw material prices. • Overall sales performance was primarily impacted by the timing of a Cystatin C order worth NOK 5.3 million pushed to subsequent quarters, with no expected negative impact on full‑year sales.
• Sales of fCAL turbo increased by 10% in Q1 2026 compared to Q1 2025 with solid performance from existing global partners. Several new accounts added in Q1 in Europe and in the USA contributing to further growth in 2026.
• Sales to the US were NOK 8.7 million in Q1 2026 vs NOK 3.8 million in Q1 2025 with good Cystatin C performance. The warehouse shift for one of our largest customers accounts for about NOK 4.5 million of the 2026 revenue.
• Gentian announced a long-term contract renewal with our partner Bühlmann Laboratories for the fCAL Turbo assay. • Following a comprehensive review of performance data and market dynamics, Gentian has decided to discontinue the NT-proBNP development program. This decision reflects disciplined portfolio prioritisation and enables reallocation of resources toward higher-return opportunities within the company’s expanding product pipeline.
Webcast The company will present the results today at 09.00 am, followed by a Q&A session. The presentation will be held as a live webcast on the company's website:
https://www.gentian.com/investor-relation/presentations
The webcast will also be available on the company website after the presentation.
IR contact: Njaal Kind, CFO njaal.kind@gentian.no +47 919 06 525 (mobile)
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act. This stock exchange announcement was published by Ole Sørlie, Business controller at Gentian Diagnostics ASA, on 6 May 2026 at 07:30 CET.
About Gentian Diagnostics Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lie within immunoassays, specifically for infections, inflammation, kidney disease and heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.